Impact of subcutaneous belimumab on disease activity, patient satisfaction, and metabolic profile in long-lasting systemic lupus erythematosus

ConclusionSubcutaneous BEL was effective in improving disease activity and proteinuria in patients with chronic disease while reducing PSL. Reduction in PSL by BEL also improved lipid status, which could synergistically reduce cardiovascular risk in SLE.Key Points• Significant reduction of disease activity, proteinuria, and prednisolone was observed in patients using subcutaneous belimumab.• Patient satisfaction was higher in terms of side effects in subcutaneous belimumab compared with prednisolone.• Reduction in prednisolone by belimumab contributed to the improvement of lipid status and would reduce the cardiovascular risk.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research